Revelation Biosciences is a life sciences company whose development of immunologic-based therapies is based on the well-established biology of phosphorylated hexaacyl disaccharide (PHAD) and its effect on the innate immune system. The company announced that the FDA has accepted its IND application for Gemini and that it expects to begin the study in early 2025.
